Effects of hydralazine and nitroprusside on cardiopulmonary function when a decrease in cardiac output complicates a...

Area of Science:

• Cardiopulmonary Physiology
• Pharmacology

Background:

• Reduced cardiac output (CO) due to increased pulmonary vascular resistance (PVR) presents a significant clinical challenge.
• Vasodilator therapy is often employed, but differential effects on hemodynamics require investigation.

Purpose of the Study:

• To compare the short-term cardiopulmonary effects of nitroprusside and hydralazine in a canine model of acutely increased PVR and reduced CO.
• To determine which vasodilator agent may be more effective in improving cardiac function under these specific conditions.

Main Methods:

• Six anesthetized, ventilated dogs underwent induced increases in PVR via autologous blood clot injection, leading to a ~40% fall in CO.
• Dogs received sequential treatment with nitroprusside and hydralazine.
• Hemodynamic parameters including biventricular filling pressures, CO, stroke volume, mean blood pressure, pulmonary artery pressure, systemic vascular resistance, and PVR were monitored.

Main Results:

• Both nitroprusside and hydralazine reduced biventricular filling pressures.
• Only hydralazine significantly increased CO and stroke volume.
• Hydralazine decreased systemic vascular resistance and PVR while maintaining blood pressure and pulmonary artery pressure.
• Nitroprusside decreased blood pressure and systemic vascular resistance but did not alter PVR or pulmonary artery pressure.

Conclusions:

• In situations where cardiac output is significantly compromised by increased pulmonary vascular resistance, hydralazine demonstrates superior efficacy over nitroprusside in enhancing cardiopulmonary function.
• Hydralazine's ability to reduce both systemic and pulmonary vascular resistance, alongside improving cardiac output, makes it a potentially advantageous therapeutic option.